Introduction
Obstructive sleep apnea syndrome (OSAS) is a chronic condition characterized by frequent episodes of upper airway collapse while sleeping, and can lead to severe complications if left untreated. The various published studies set the prevalence of OSAS in the range of 3-7 %, with some groups in the general population carrying a higher risk [1] . OSAS is experienced as interruptions in breathing, or waking due to gasping or choking, and diagnosed in cases with at least five obstructive respiratory events (apneas, hypopneas, or respiratory effort-related arousals) per hour of sleep. The presence of 15 or more obstructive respiratory events per hour of sleep in the absence of sleep-related symptoms also suffices for a diagnosis of OSAS [2, 3] .
More attention has been paid to OSAS in recent years. This review focuses on the close link between sleep apnea and several endocrinological and metabolic conditions, because OSAS leads to significant changes in the serum levels or secretory patterns of several hormones, and apnea may lie behind endocrine disease. Physicians should suspect OSAS in patients who report habitual and continuous snoring, daytime drowsiness, or other sleep-related signs or symptoms, associated with cardiovascular or metabolic diseases (as summarized in Table 1 ). Several screening questionnaires have been developed to identify patients with OSAS in high-risk populations (the most widely used are the Berlin questionnaire and the STOP-BANG screening test), but none are sufficiently accurate to preclude the need for formal sleep testing [3] .
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In a patient suspected of having OSAS, physicians should consider polysomnography or cardiorespiratory monitoring to assess the condition's severity. Both methods measure the number of upper airway obstructions, be they full (apnea: breathing cessation for ≥10 s) or partial (hypopnea: breathing flow reduction for ≥10 s, accompanied by oxyhemoglobin desaturation or arousal from sleep). Both polysomnography and cardiorespiratory monitoring estimate the Apnea-Hypopnea Index (AHI: number of apnea/ hypopnea episodes per hour), which is used to define OSAS as mild (5 ≤ AHI < 15), moderate (15 ≤ AHI < 30), or severe (AHI ≥ 30) [3] .
The round trip between OSAS and metabolic syndrome
The relationship between OSAS and type 2 diabetes (T2D) has been studied extensively in the literature, and OSAS is an independent risk factor for the onset of T2D [4] [5] [6] . Furthermore, diabetic patients also tend to have additional risk factors for OSAS, such as obesity, hypertension, and metabolic syndrome. The prevalence of T2D in patients with OSAS is in the range of 15-30 %, depending on the study population or the OSAS definition considered; and the prevalence of OSAS in patients with T2D is high (up to 30-40 % [7, 8] ), even after controlling for several confounding factors (age, sex, obesity [6] ).
Intermittent hypoxia in OSAS leads to β-cell death in mice model, related to oxidative stress, because the overexpression of antioxidant proteins completely abrogated the effects of hypoxia on cell metabolism [9] . Severe OSAS is associated with a worsening glucose control, and not only in obese subjects [5] . Recent studies have reported a 27 % lower insulin sensitivity, and a 37 % higher insulin secretion in healthy lean men with OSAS than in controls after oral glucose tolerance test, despite comparable baseline serum glucose levels and even after matching for confounding factors. This would suggest that OSAS is associated with insulin resistance, leading to an increased risk of T2D independent of the traditional cardiometabolic risk factors [10] .
OSAS is related to micro-and macrovascular diabetic complications, having the same molecular consequences that contribute to endothelial dysfunction, i.e., oxidative and nitrosative stress, protein kinase C activation, increased vascular endothelial growth factor, local inflammation, and non-alcoholic steatohepatitis [5, 6] . Cross-sectional studies have also found that OSAS associated with diabetic retinopathy: Shiba et al. described that OSAS is a potential risk factor for the progression of diabetic retinopathy, suggesting that nocturnal intermittent desaturation and reoxygenation occurs at a high frequency in patients with T2D [11] .
Apart from diabetes and glucose levels, several authors have recently reported that visceral obesity and OSAS share some mechanisms (especially hypoxia), because many of the secretory responses of adipocytes are initiated at PO 2 levels above the normal physiological range for adipose tissue (since in obese subjects there is an increase in the distance between adipocytes and capillaries [12] ). Several mechanisms are involved in the association between obesity and OSAS: collapsibility of the peripharyngeal tissues; accumulation of adipose tissue in the neck; limited chest wall dynamics; impaired respiratory muscle function; and neuroendocrine regulation of food ingestion [13, 14] . Whether continuous positive airway pressure (CPAP) therapy is able to improve metabolic control is not clearly established yet: there is a great debate about the possible positive effects of CPAP treatment on glucose levels in patients with T2D. Some authors reported that CPAP did not reverse glucose intolerance [15, 16] or improve insulin sensitivity and metabolic control (HbA1c levels); contrariwise other study reported that 3 months of CPAP reduced HbA1c levels, as well as body weight, so it is unclear whether the metabolic improvement was linked to CPAP treatment or to the reduction of obesity [17] . Moreover, lifestyle changes, including daily physical activity, improved sleep hygiene, and dietary adjustments improve not only metabolic syndrome, but also OSAS, especially in obese patients [6] . In obese subjects with prolactinoma, Barbosa et al. described that OSAS prevalence is similar to the obese controls: weight and visceral obesity (and not prolactin levels) were the major factor involved in the occurrence of sleep disorders, indeed OSAS symptoms did not improve after dopamine-agonist treatment [18] . Although adenotonsillar hypertrophy emerges as one of the major contributing factors to OSAS in children and adolescences than in adults, recently some authors reported that even obesity plays an important contributory role to the pathophysiology of OSAS in young subjects [19] . A particular case concerns Prader-Willi Syndrome (PWS), a genetic disorder affecting chromosome 15q11-q13 and characterized by excessive eating secondary to a hypothalamic dysfunction, which leads to severe obesity. The prevalence of OSAS is high among PWS children: there are several factors, other than obesity, involved in inducing OSAS in PWS children, including GH deficiency, increased viscosity of secretions, and craniofacial abnormalities that give rise to collapsible, small caliber airways [20, 21] .
OSAS and the hypothalamic-pituitary-thyroid axis
The relationship between OSAS and hypothyroidism has been the object of many authors' interest: while respiratory disturbances during sleep are common in patients suffering from hypothyroidism, it is not clear whether OSAS and hypothyroidism are merely associated diseases (since the two conditions share several common signs) [22] [23] [24] [25] [26] . In fact, the incidence of hypothyroidism in OSAS patients is not known for sure [23] [24] [25] [26] , and large goiters can also cause pharyngeal occlusion regardless of thyroid function (as shown in Fig. 1 ). Mete et al. recently studied thyroid function and performed thyroid ultrasound in 150 consecutive patients with polysomnographically confirmed OSAS, finding no difference in the prevalence of hypothyroidism, the number of nodules, or parenchyma echogenicity between OSAS patients and controls [25] . On the other hand, Resta et al. reported a prevalence of previously undiagnosed subclinical hypothyroidism of 11 % in subjects referred to a sleep clinic for polysomnography, with higher BMIs and Epworth sleepiness scores in the hypothyroid subjects, and they suggested that thyroid function should always be assessed in obese patients with OSAS [24] . Apart from obesity, severe hypothyroidism with myxedema is also associated with decreased ventilatory responses, albumin extravasation, excess mucopolysaccharides in the upper airway tissues, and myopathy [26] . While contrasting data are available on the efficacy of thyroid replacement therapy in improving OSAS symptoms in hypothyroid patients [23, 26] , Bratel et al. reported that CPAP treatment caused reduction in serum TSH [22] .
OSAS and growth hormone (GH)
There is a well-established, close relationship between GH and OSAS [27, 28] . Large goiters are found in up to 73 % of patients with acromegaly [29] , who also have a high prevalence of T2D [27] , but thyroid size and glucose metabolism are not sufficient to explain the association of OSAS with acromegaly. GH and IGF-1 excess lead to anatomical changes on craniofacial bones, soft tissues, and respiratory mucosa, so patients very frequently develop OSAS (up to 80-90 % in many series [27, 30, 31] ), with daytime sleepiness, and cognitive impairment severe enough to affect quality of life (QoL) [32] . Acromegaly is also associated with the so-called "central" apnea, which stems from changes in the non-behavioral system controlling ventilation that are related to direct effects of GH/IGF-I levels on the breathing center [27] . Rather than GH/IGF-1 excess, Vannucci et al. described that in acromegalic patient smoking, female gender, and presence of lung disease appear to lead to more severe sleep apnea [31] . CPAP treatment is effective to control sleep disorders in acromegaly [30] , while there are discordant results about GH/IGF-1 normalization and OSAS improvement: Chemla et al. reported that acromegaly control (obtained by surgery or with medical treatment) had no significant effect on polysomnographic indices [33], whereas Berg et al. described that successful 
Patients with GH deficiency (GHD) can develop central obesity and impaired glucose metabolism, thus increasing the risk of sleep disorders [28] . The effect of GH supplementation in sleep apnea on patients with GHD is a matter of debate, because some authors have suggested that GH might induce or exacerbate OSAS [35] . In a prospective observational study, Peker et al. found not only that GH replacement therapy did not induce or aggravate OSAS in adults with GHD, but also that this therapy increased the proportion of rapid eye movement (REM) sleep and improved patients' QoL [28] . Salvatoni et al. also reported that 6-week GH treatment did not cause upper airway restriction in a group of children with PWS [36] . Obesity coincides with an impaired GH secretion: Gianotti et al. described that GH response to arginine plus GHRH test in OSAS subjects was lower than in obese controls, and in the latter than lean subjects [37] .
OSAS and sex hormones
In males, lower testosterone levels are associated with a deterioration in sleep efficiency and more frequent awakenings, especially in the elderly [38, 39] . Changes in nocturnal testosterone secretion are sleep related, with levels rising during sleep and falling on waking, whereas circadian variations are apparently marginal [38] . Peak testosterone levels also coincide with the onset of REM sleep [40] : in older men some sleep disturbances (i.e., fewer episodes of REM sleep and altered REM sleep latency) are associated with lower circulating testosterone concentrations [40] , and in women lower levels of sex hormones (17OH progesterone, progesterone, and estradiol) are associated with an AHI > 10, even after matching for age and time point after the last menstrual cycle [41] . In a prospective study, Celec et al. demonstrated in obese eugonadal subjects with OSAS that CPAP treatment did not affect testosterone or estradiol levels in patients of either gender [42] , similar results are confirmed in a recent meta-analysis [43] . Gambineri et al. found testosterone levels lower in obese OSAS patients than in obese controls, with a negative correlation between their polysomnographic parameters and testosterone levels, suggesting that the severity of hypoxia may be an additional factor in reducing testosterone levels, regardless of BMI [44] . Regarding replacement therapy, in a 18-week randomized, double-blind, placebocontrolled trial in 67 men Hoyos et al. reported that androgen therapy in obese men with severe OSAS mildly worsens sleep-disordered breathing, irrespective of initial testosterone concentrations [45] , but the overall risk benefits on OSAS of testosterone therapy in men with the lowest blood testosterone concentrations are yet to be defined.
In young women, aspects of metabolic syndrome, insulin resistance, and androgen excess are related to polycystic ovarian syndrome (PCOS), and standardized questionnaires revealed that OSAS is highly prevalent in adolescents with PCOS compared with matched controls [46] . Tasali et al. reported that CPAP treatment improved insulin sensitivity in 19 young obese females with PCOS [47], and Tock et al. described that in 38 PCOS patients the presence of OSAS was an independent predictor of non-alcoholic fatty liver disease (NAFLD), the prevalence of which was higher in patients with OSAS than in those without, moreover they observed a higher AHI in patients with NAFLD [48] .
OSAS and the hypothalamic-pituitary-adrenal (HPA) axis: to sleep or to stress?
Apnea episodes usually occur at night, a crucial time for HPA axis physiology: cortisol secretion is controlled by several factors, among which the principal is the early morning secretion of ACTH [49] . Although many studies have failed to identify differences in cortisol levels between patients with OSAS and healthy controls [50, 51] , Karaca et al. recently studied 26 patients with OSAS and 15 healthy non-smoker volunteers, testing both HPA axis suppression (with the dexamethasone suppression test, DST) and stimulation (with 1-250 µg ACTH and glucagon). Serum basal and peak cortisol levels were found lower in OSAS patients than in controls during the 1 µg ACTH and glucagon stimulation tests, with a positive correlation between BMI and AHI [51] . It is noteworthy that 1 of the 26 OSAS patients in the Karaca study had an inadequate cortisol response to all the three stimulation tests: although such a small series cannot be assumed to reflect the situation of OSAS patients generally, from an endocrine standpoint this patient was a case of undiagnosed adrenal insufficiency-which is a life-threatening condition.
Mild HPA axis activation (the pseudo-cushing's state) usually occurs in the cases of major depression, pregnancy, anorexia nervosa, alcoholism, diabetes mellitus, and simple obesity [52] , but contrasting data are reported in literature about HPA axis activation and OSAS. Carniero et al. studied the effect of CPAP on the HPA axis in 29 obese men: salivary cortisol levels after DST were lower in the patients who had OSAS than in those who did not; and after CPAP therapy, OSAS patients showed a greater cortisol suppression after DST that correlated positively with an improvement in AHI [50] . Vgontzas et al. reported that administering CRH prompted a stronger ACTH response in obese patients, concluding that low cortisol secretion in obesity might predispose the obese to OSAS [53] , and similarly Lanfranco et al. described a more remarkable enhancement of the ACTH response to CRH in obese patients with OSAS [54] , suggesting that HPA axis impairment could result from hypothalamic CRH hyposecretion or increased peripheral clearance of cortisol in obese subjects.
Cushing's syndrome (CS) is secondary to a chronic glucocorticoid excess [55] , and some papers have described cases of OSAS in patients with endogenous or iatrogenic CS [56, 57] . Since CS patients may present with severe metabolic syndrome, it may be difficult to establish the exact role of hypercortisolism, obesity, diabetes, or hypertension in the onset of OSAS, because sleep disorders could be also related to direct cortisol-induced myopathy (skeletal muscle weakness and limited activity of the geniohyoid and genioglossus muscles [56] [57] [58] ).
OSAS and hypertension: not just metabolic syndrome
Prospective studies have suggested an association between hypertension and OSAS because patients with a high AHI (>15) had a three-fold risk of hypertension, and the incidence of hypertension was higher among patients who refused CPAP [59] . The proposed mechanism for this association is a pattern of intermittent hypoxia that causes an increase in sympathetic tone, endothelin secretion, endothelial dysfunction/inflammation, impaired glucose metabolism, and HPA axis activation [5, 8, [59] [60] [61] . The incidence of OSAS is also higher in patients with resistant hypertension (high blood pressure despite three antihypertensives) [59, 62] .
Aldosterone excess may play a pathophysiological part in the relationship between hypertension and OSAS, since higher plasma aldosterone concentrations and OSAS were seen in patients with refractory hypertension [63] , and the prevalence of OSAS was higher in subjects with primary hyperaldosteronism than in patients with essential hypertension [64] . In 2004 Calhoun et al. studied the reninaldosterone axis in more than 100 patients with OSAS: subjects at high risk of OSAS were almost twice as likely to have primary aldosteronism and tended to have lower renin levels [65] . It is worth noting that, in addition to a close relationship between OSAS and hypertension, some authors have also reported that treating OSAS leads to a modest, but significant, reduction in blood pressure (from 2 to 5 mmHg) in patients with resistant hypertension, with a consequent important reduction in their cardiovascular risk [59] .
The sudden arousal from sleep typical of obese OSAS patients causes a transient surge in sympathetic nerve activity, with consequent elevations in 24-h urinary catecholamine levels [59] . In 2004 Hoy et al. reported on 5 OSAS patients with hypertension and a biochemical picture of pheochromocytoma, but no catecholamine-secreting tumor:
treating OSAS with CPAP led to a normalization of both pressure and catecholamine levels [66] .
OSAS and bone metabolism
Bone homeostasis is profoundly affected by local pH and oxygen: the repetitive hypoxia-reoxygenation phenomena in patients with OSAS may induce oxidative stress and acidosis, affecting bone metabolism and microarchitecture, because hypoxia may either inhibit osteoblasts differentiation or stimulate osteoclast formation [67] . Several papers report a vicious circle between vitamin D deficiency, OSAS, and glucose metabolism: patients with severe OSAS had lower vitamin D levels [68] , the risk of osteoporosis in the OSAS cohort was 2.74 times than patients without sleep disorders [69] , and recently some authors reported that vitamin D deficiency (closely linked to osteoporosis and diabetes) may play a role and worsen OSAS's adverse outcomes and comorbidities, especially those regarding glucose metabolism [70, 71] .
OSAS treatment
Treatment for OSAS includes lifestyle changes (weight loss, cessation of alcohol ingestion in the evenings, sleep position training), upper airway surgery, CPAP, and the use of oral devices [72] [73] [74] .
Various surgical techniques (maxillomandibular advancement, radiofrequency surgery on the soft palate, multilevel surgery) for enlarging the upper airway may be an option for OSAS in carefully selected patients refractory to CPAP and other conservative therapies [73] , but the benefit should be weighed against the risk of complications. Adenotonsillectomy is associated with improvements in polysomnographic findings and subjective symptoms in pediatric OSAS patients, also restoring a normal pituitaryadrenal axis [75] .
CPAP is the initial treatment of choice because it is noninvasive and technically effective [72] . The CPAP device is worn nightly and acts as a constant pressure air splint, preventing upper airway collapse during sleep. Removable oral devices are fitted to the teeth to advance the mandible during sleep improves nocturnal breathing disturbances and subjective daytime sleepiness, thus improving QoL for OSAS patients [71, 73] . This solution is recommended for patients with mild to moderate OSAS who prefer an oral device to CPAP, or fail to respond to CPAP [72] . Compliance with oral devices is reportedly higher than with CPAP [76] , and patients often prefer them [77] [78] [79] [80] . There is also emerging evidence of oral devices having beneficial cardiovascular effects, especially in improving cardiac autonomic modulation [81] .
Conclusions
OSAS is a high prevalence condition, especially in patients with metabolic syndrome or endocrine disorders. Early diagnosis of sleep apnea is mandatory, since its prompt treatment could improve blood pressure or glucose tolerance. 
